Pharmaceutical

Merck decides to acquire Peloton Therapeutics, fortifying Oncology pipeline Merck is ready to buy Peloton Therapeutics for USD 1.1 million. The companies have entered into a definitive agreement which will give Merck rights over an oral HIF-2α inhibitor- PT2977, which is Peloton’s lead candidate for the treatment of renal cancer. The collaboration will help Merck achieve its goal to develop novel therapies through innovative research for the treatment of cancer. PT2977 here is underway for multiple clinical studies specifically for von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC). Amgen to buy a drug discovery company Nuevolution Amgen ...